Roche announced positive topline results from its Phase II ZUPREME-1 trial for petrelintide, an amylin analog designed for chronic weight management. The study involved 493 participants with overweight or obesity (mean BMI of 37 kg/m²) and demonstrated that once-weekly subcutaneous injections of petrelintide led to statistically significant and clinically meaningful weight loss compared to placebo. At week 42, participants achieved up to a 10.7% mean body weight reduction, while the placebo group saw only a 1.7% reduction, with a p-value of less than 0.001.
A key finding was petrelintide's favorable tolerability profile, which was comparable to placebo. The study reported no unexpected safety signals. Specifically, the maximally effective dose of petrelintide had no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. The overall treatment discontinuation rate due to adverse events for petrelintide in the maximally effective arm was 4.8%, similar to placebo's 4.9%. Gastrointestinal adverse events, when they occurred, were mostly mild, and rates of diarrhea and constipation remained in the single digits, consistent with placebo.
This strong tolerability distinguishes petrelintide from other weight-loss medications like GLP-1 agonists, which often have higher rates of gastrointestinal side effects. For instance, oral semaglutide 25 mg reported nausea in 46.6% of participants and vomiting in 30.9% in its OASIS 4 trial ft.com. Eli Lilly's orforglipron also showed higher rates of nausea (up to 35.9%) and vomiting (up to 24.0%) prnewswire.com. Roche highlights that petrelintide's excellent tolerability not only supports its development as a monotherapy but also confirms its potential as a combination partner with other treatments.
Compared to other weight-loss drugs, petrelintide's 10.7% weight loss is promising, though some GLP-1 agonists have shown higher efficacy. For example, Novo Nordisk's oral semaglutide 25 mg achieved an average weight loss of 16.6% at 64 weeks ft.com, and Eli Lilly's orforglipron showed up to 12.4% weight loss at 72 weeks for its highest dose prnewswire.com. However, petrelintide's unique tolerability profile could make it a preferred option for patients sensitive to the gastrointestinal side effects common with other therapies, offering a differentiated approach in the competitive obesity treatment market.
